Form D · Pharmaceuticals

ACHILLION PHARMACEUTICALS INC

New Haven, CT · CIK 0001070336

Offering snapshot reported Aug 23, 2010 · SEC filing

Reported sold
$50.1M
Offering amount: $50.1M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 20, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 23, 2010Initial$50,105,162No comparison6SEC filing
Aug 18, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Dec 6, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-146800

Source: Form D, filed Aug 23, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Milind S. Deshpande Executive
Mary Kay Fenton Executive
Jason S. Fisherman Director
Gary E. Frashier Director
Michael Grey Director
Michael D. Kishbauch Director, Executive
Dennis C. Liotta Director
Elizabeth Olek Executive
David I. Scheer Director
Gautam Shah Executive
Nicholas J. Simon Director
Joseph Truitt Executive
Robert L. Van Nostrand Director
David P. Wright Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
300 George Street
New Haven, CT, 06511